beta
Trial Radar AI
Clinical Trial NCT06433817 for Cervical Cancer, Radiotherapy is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Spectral CT in Radiotherapy for Cervical Cancer 150

Recruiting
Clinical Trial NCT06433817 is an observational study for Cervical Cancer, Radiotherapy that is recruiting. It started on 22 May 2024 with plans to enroll 150 participants. Led by Peking Union Medical College Hospital, it is expected to complete by 31 December 2026. The latest data from ClinicalTrials.gov was last updated on 30 May 2024.
Brief Summary
The purpose of this study was to explore the potential application of spectral CT for radiotherapy in cervical cancer.
Official Title

The Clinical Research of Spectral CT in Radiotherapy for Cervical Cancer

Conditions
Cervical CancerRadiotherapy
Other Study IDs
  • SPRTCC-Trial
NCT ID Number
NCT06433817
Start Date (Actual)
2024-05-22
Last Update Posted
2024-05-30
Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
150
Study Type
Observational
Status
Recruiting
Arms / Interventions
Participant Group/ArmIntervention/Treatment
N/A
Spectral computed tomography scan
Spectral CT scans acquisition performed during the arterial phase and venous phase for cervical cancer
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Comparison of spectral CT derived data with response evaluation in cervical cancer
To evaluate the tumor response of using quantitative parameters in spectral CT for cervical cancer patients according to RECIST 1.1
through study completion, an average of 2 year
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Identifying metastatic lymph nodes in cervical cancer with spectral CT
To evaluate the diagnostic performances of using spectral CT for identifying metastatic lymph nodes in patients with cervical cancer
through study completion, an average of 2 year
Application of energy spectrum CT in brachytherapy of cervical cancer
The ability to reduce metal artifact and assist in target delineation
through study completion, an average of 2 year
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
  1. All patients were confirmed cervical cancer by pathology
  2. patients were treated with concurrent chemoradiotherapy
  3. Spectral CT scans acquisition performed during the arterial phase and venous phase
  4. All the patients underwent a 18F-FDG PET/CT before treatment

  1. CT without spectral scans
  2. History of allergy to intravenous contrast
  3. Pregnant or potentially pregnant female subjects
Peking Union Medical College Hospital logoPeking Union Medical College Hospital482 active studies to explore
Study Central Contact
Contact: Fuquan Zhang, Porf, 86 01069154072, [email protected]
1 Study Locations in 1 Countries

Beijing Municipality

Peking Union Medical College Hospital, Beijing, Beijing Municipality, 100010, China
Zheng Zeng, MD., Contact, 86 01069154073, [email protected]
Recruiting